Vor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease

MT Newswires Live06-08

Vor Bio (VOR) and RemeGen said Monday China's National Medicinal Products Administration approved telitacicept to treat adults with Sjogren's disease.

The approval makes it the first authorized treatment for the condition in China. The approval followed RemeGen's phase 3 trial, which demonstrated significant improvements in patient symptoms and systemic disease activity, the company said.

RemeGen developed telitacicept to treat the chronic autoimmune condition, and Vor Bio maintains the sole rights to develop and market the therapy outside of Greater China, it added.

Shares of the company were up 1.1% in Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641726482?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641726482","market":"hk","top_or_hot":-1,"title":"Vor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease","media":"MT Newswires Live","content":"<html><body><p> Vor Bio (VOR) and RemeGen said Monday China's National Medicinal Products Administration approved telitacicept to treat adults with Sjogren's disease.</p><p>The approval makes it the first authorized treatment for the condition in China. The approval followed RemeGen's phase 3 trial, which demonstrated significant improvements in patient symptoms and systemic disease activity, the company said.</p><p>RemeGen developed telitacicept to treat the chronic autoimmune condition, and Vor Bio maintains the sole rights to develop and market the therapy outside of Greater China, it added.</p><p>Shares of the company were up 1.1% in Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-08 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Vor Bio (VOR) and RemeGen said Monday China's National Medicinal Products Administration approved telitacicept to treat adults with Sjogren's disease.</p><p>The approval makes it the first authorized treatment for the condition in China. The approval followed RemeGen's phase 3 trial, which demonstrated significant improvements in patient symptoms and systemic disease activity, the company said.</p><p>RemeGen developed telitacicept to treat the chronic autoimmune condition, and Vor Bio maintains the sole rights to develop and market the therapy outside of Greater China, it added.</p><p>Shares of the company were up 1.1% in Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VOR","symbol_name":"Vor Biopharma Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641726482","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641726482","pubTimestamp":1780925414,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vor Bio  and RemeGen said Monday China's National Medicinal Products Administration approved telitacicept to treat adults with Sjogren's disease.The approval makes it the first authorized treatment for the condition in China. The approval followed RemeGen's phase 3 trial, which demonstrated significant improvements in patient symptoms and systemic disease activity, the company said.RemeGen developed telitacicept to treat the chronic autoimmune condition, and Vor Bio maintains the sole rights to develop and market the therapy outside of Greater China, it added.Shares of the company were up 1.1% in Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VOR":"Vor Biopharma Inc.","BK4139":"生物科技"},"translate_title":"Vor Bio合作伙伴药物在中国获得监管机构批准治疗干燥综合征","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOR":1},"content_text":"Vor Bio (VOR) and RemeGen said Monday China's National Medicinal Products Administration approved telitacicept to treat adults with Sjogren's disease.The approval makes it the first authorized treatment for the condition in China. The approval followed RemeGen's phase 3 trial, which demonstrated significant improvements in patient symptoms and systemic disease activity, the company said.RemeGen developed telitacicept to treat the chronic autoimmune condition, and Vor Bio maintains the sole rights to develop and market the therapy outside of Greater China, it added.Shares of the company were up 1.1% in Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641726482","isCrawlerRequest":true}